Repurposing azithromycin for neonatal neuroprotection.

ABSTRACT: BACKGROUND:Inflammation contributes to neonatal hypoxic-ischemic brain injury pathogenesis. We evaluated the neuroprotective efficacy of azithromycin, a safe, widely available antibiotic with anti-inflammatory properties, in a neonatal rodent hypoxic-ischemic brain injury model. METHODS:Seven-day-old rats underwent right carotid artery ligation followed by 90-min 8% oxygen exposure; this procedure elicits quantifiable left forepaw functional impairment and right cerebral hemisphere damage. Sensorimotor function (vibrissae-stimulated forepaw placing, grip strength) and brain damage were compared in azithromycin- and saline-treated littermates 2-4 weeks later. Multiple treatment protocols were evaluated (variables included doses ranging from 15 to 45?mg/kg; treatment onset 15?min to 4?h post-hypoxia, and comparison of 1 vs. 3 injections). RESULTS:All azithromycin doses improved function and reduced brain damage; efficacy was dose dependent, and declined with increasing treatment delay. Three azithromycin injections, administered over 48?h, improved performance on both function measures and reduced brain damage more than a single dose. CONCLUSION:In this neonatal rodent model, azithromycin improved functional and neuropathology outcomes. If supported by confirmatory studies in complementary neonatal brain injury models, azithromycin could be an attractive candidate drug for repurposing and evaluation for neonatal neuroprotection in clinical trials.

SUBMITTER: Barks JDE 

PROVIDER: S-EPMC6764891 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature